U.S. PHARMACOPEIA

Search USP29  
Quinine Sulfate Tablets
» Quinine Sulfate Tablets contain amounts of quinine sulfate and dihydroquinine sulfate totaling not less than 90.0 percent and not more than 110.0 percent of the labeled amount of quinine sulfate, calculated as (C20H24N2O2)2·H2SO4·2H2O.
Packaging and storage— Preserve in well-closed containers.
Identification—
A: Shake well a quantity of powdered Tablets, equivalent to about 100 mg of quinine sulfate, with 100 mL of dilute sulfuric acid (1 in 350), and filter. An appropriate dilution of the filtrate exhibits a vivid blue fluorescence. On the addition of a few drops of hydrochloric acid the fluorescence disappears.
B: In the test for Chromatographic purity, the RF value of the principal spot obtained from the Test preparation corresponds to that from the Standard preparation.
C: Shake a quantity of powdered Tablets, equivalent to about 20 mg of quinine sulfate, with 10 mL of dilute hydrochloric acid (1 in 100), and filter: the filtrate responds to the tests for Sulfate 191.
D: The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, obtained as directed in the Assay.
Dissolution 711
Medium: 0.01 N hydrochloric acid; 900 mL.
Apparatus 1: 100 rpm.
Time: 45 minutes.
Procedure— Determine the amount of (C20H24N2O2)2·H2SO4 · 2H2O dissolved by employing UV absorption at the wavelength of maximum absorbance at about 248 nm on filtered portions of the solution under test, suitably diluted with Dissolution Medium, in comparison with a Standard solution having a known concentration of USP Quinine Sulfate RS in the same Medium.
Tolerances— Not less than 75% (Q) of the labeled amount of (C20H24N2O2)2·H2SO4·2H2O is dissolved in 45 minutes.
Uniformity of dosage units 905: meet the requirements.
Procedure for content uniformity— Proceed as directed for Procedure for content uniformity under Uniformity of dosage units under Quinine Sulfate Capsules, using 1 powdered Tablet instead of the contents of 1 Capsule.
Chromatographic purity— Shake a quantity of powdered Tablets, equivalent to about 150 mg of quinine sulfate, with 25 mL of diluted alcohol for 10 minutes, and filter. Using this as the test solution, proceed as directed in the test for Chromatographic purity under Quinine Sulfate.
Residual solvents 467: meet the requirements.
(Official January 1, 2007)
Assay—
Methanesulfonic acid solution, Diethylamine solution, Mobile phase, System suitability preparation , and System suitability test—Proceed as directed in the test for Limit of dihydroquinine sulfate under Quinine Sulfate.
Standard preparation— Transfer about 20 mg of USP Quinine Sulfate RS, accurately weighed, to a 100-mL volumetric flask, dissolve in and dilute with Mobile phase to volume, and mix.
Assay preparation— Weigh and finely powder not less than 20 Tablets. Transfer an accurately weighed portion of the powder, equivalent to about 160 mg of quinine sulfate, to a 100-mL volumetric flask, add 80 mL of methanol, and shake the flask by mechanical means for 30 minutes. Dilute with methanol to volume, and filter, discarding the first 10 mL of the filtrate. Transfer 3.0 mL of the filtrate to a 25-mL volumetric flask, dilute with Mobile phase to volume, and mix.
Procedure (see Chromatography 621)—Inject equal volumes (about 50 µL) of the Standard preparation and the Assay preparation into a chromatograph equipped with a 235-nm detector and a 3.9-mm × 30-cm column that contains packing L1. Calculate the quantity, in mg, of the sum of quinine sulfate and dihydroquinine sulfate in the portion of Tablets taken by the formula:
(2500 / 3)C(rb,U + rd,U) / (rb,S + rd,S),
in which C is the concentration, in mg per mL, of USP Quinine Sulfate RS in the Standard preparation, rb,U and rb,S are the peak area responses of quinine obtained from the Assay preparation and the Standard preparation, respectively, and rd,U and rd,S are the peak area responses of dihydroquinine obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Staff Liaison : Behnam Davani, Ph.D., MBA, Senior Scientist
Expert Committee : (MDAA05) Monograph Development-Antivirals and Antimicrobials
USP29–NF24 Page 1887
Phone Number : 1-301-816-8394